The Ministry of Food and Drug Safety ordered a nationwide recall of one lot of imported losartan-potassium tablets Friday after stability tests found N-nitrosodimethylamine above interim limits, affecting roughly 120,000 packs dispensed since August.

Lot 9C441, imported by a Seoul distributor from an Indian contract manufacturer, is used primarily for hypertension control in adults. MFDS said patients should not stop treatment abruptly but should return unused pills to pharmacies for replacement lots cleared this week.

How the impurity was found

Routine post-market sampling flagged the nitrosamine in mid-October, triggering a 72-hour verification cycle with the National Institute of Food and Drug Safety Evaluation. Confirmatory tests completed Thursday night showed NDMA at 0.92 micrograms per tablet, above Korea’s interim cap of 0.82 micrograms for this molecule.

The distributor halted new shipments and notified hospitals by emergency fax overnight. Community pharmacies received barcode alerts through the national drug tracking system Friday morning.

Patient guidance

MFDS said the exposure window is shorter than prior valsartan recalls and estimated population cancer risk as low, but it still mandated recall class I—the highest urgency—because hypertension patients skew older with comorbidities.

Telehealth platforms added banner warnings on electronic prescriptions tied to the lot number, and the National Health Insurance Service said copays on replacement drugs will not be charged twice when swaps occur at the same pharmacy.

Manufacturer response

The Indian manufacturer told MFDS it changed a solvent supplier in June and will submit root-cause analysis within two weeks. Korean regulators said they will inspect the plant remotely before approving future imports from the site.

Pharmacy operations

The Korean Pharmaceutical Association activated a weekend staffing line so rural pharmacies could receive replacement lots by courier rather than waiting for Monday wholesale deliveries. MFDS posted QR codes linking to lot-check tools after complaints that elderly patients struggled with small print on blister packs.

Major hospital chains said they would swap affected inpatient supplies automatically during medication reconciliation rounds, reducing the burden on ward nurses to identify the lot numbers manually.

Import controls

MFDS said it would hold shipments from the Indian plant at border inspection until third-party lab certificates arrive for the next three lots, extending review times by up to five days for hypertension generics from that site.

Community health centers in Gyeonggi said they would extend weekend hours until the recall clears, citing a spike in phone inquiries from patients unsure whether their blister packs matched the affected lot code.